Ertugliflozin; Metformin Hydrochloride Patent Expiration

Ertugliflozin; Metformin Hydrochloride is Used for improving glycemic control in adults with type 2 diabetes. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc in its drug Segluromet on Dec 19, 2017.


Ertugliflozin; Metformin Hydrochloride Patents

Given below is the list of patents protecting Ertugliflozin; Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Segluromet US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Oct 21, 2030 Msd Sub Merck
Segluromet US9439902 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Oct 21, 2030 Msd Sub Merck
Segluromet US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Jul 13, 2030 Msd Sub Merck



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ertugliflozin; Metformin Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Ertugliflozin; Metformin Hydrochloride.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
Payment of Maintenance Fee, 12th Year, Large Entity 10 May, 2023 US8080580
Second letter to regulating agency to determine regulatory review period 22 Apr, 2021 US8080580
Second letter to regulating agency to determine regulatory review period 15 Apr, 2021 US8080580
Letter from FDA or Dept of Agriculture re PTE application 12 Jun, 2019 US8080580
Payment of Maintenance Fee, 8th Year, Large Entity 14 May, 2019 US8080580
Initial letter Re: PTE Application to regulating agency 15 Oct, 2018 US8080580
Patent Term Extension Application under 35 USC 156 Filed 15 Feb, 2018 US8080580
Recordation of Patent Grant Mailed 20 Dec, 2011 US8080580
Patent Issue Date Used in PTA Calculation 20 Dec, 2011 US8080580


Ertugliflozin; Metformin Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List